No­vo Nordisk to spend $747M+ on ex­pan­sions and new fa­cil­i­ty in Den­mark

The Dan­ish phar­ma gi­ant No­vo Nordisk is mak­ing a ma­jor ex­pan­sion close to home.

The com­pa­ny an­nounced on Tues­day that it plans to in­vest 5.4 bil­lion Dan­ish kro­ner ($747.2 mil­lion) in­to ex­pand­ing its ex­ist­ing fa­cil­i­ties in its home­town of Bagsværd, Den­mark, a sub­urb of Copen­hagen. Those plans al­so in­clude the con­struc­tion of a new plant.

A No­vo Nordisk spokesper­son did not con­firm the size of the new plant to End­points News by press time. How­ev­er, they did tell End­points that de­spite the ex­pan­sion of ex­ist­ing fa­cil­i­ties, the man­u­fac­tur­ing of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) is cur­rent­ly on­go­ing to sup­port clin­i­cal tri­als. The ex­pan­sions are ex­pect­ed to be fi­nal­ized and ful­ly op­er­a­tional in Au­gust of next year for pu­rifi­ca­tion. The new fa­cil­i­ty, which is cen­tered around fer­men­ta­tion and re­cov­ery, is ex­pect­ed to be fi­nal­ized in Au­gust 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER